Dafna Capital Management Lowered Its Loxo Oncology (LOXO) Stake; Deciphera Pharmaceuticals (DCPH) Shorts Up By 27.22%

January 14, 2018 - By Dolores Ford

Dafna Capital Management Llc decreased Loxo Oncology Inc (LOXO) stake by 13.67% reported in 2017Q3 SEC filing. Dafna Capital Management Llc sold 41,500 shares as Loxo Oncology Inc (LOXO)’s stock rose 10.54%. The Dafna Capital Management Llc holds 262,121 shares with $24.15M value, down from 303,621 last quarter. Loxo Oncology Inc now has $2.69B valuation. The stock increased 1.27% or $1.13 during the last trading session, reaching $89.99. About 440,691 shares traded. Loxo Oncology, Inc. (NASDAQ:LOXO) has risen 77.12% since January 14, 2017 and is uptrending. It has outperformed by 60.42% the S&P500.

Deciphera Pharmaceuticals Incorporated (NASDAQ:DCPH) had an increase of 27.22% in short interest. DCPH’s SI was 63,100 shares in January as released by FINRA. Its up 27.22% from 49,600 shares previously. With 106,400 avg volume, 1 days are for Deciphera Pharmaceuticals Incorporated (NASDAQ:DCPH)’s short sellers to cover DCPH’s short positions. The stock decreased 1.80% or $0.45 during the last trading session, reaching $24.54. About 224,160 shares traded or 25.29% up from the average. Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) has 0.00% since January 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Analysts await Loxo Oncology, Inc. (NASDAQ:LOXO) to report earnings on March, 6. They expect $-1.27 EPS, up 0.78% or $0.01 from last year’s $-1.28 per share. After $-1.12 actual EPS reported by Loxo Oncology, Inc. for the previous quarter, Wall Street now forecasts 13.39% negative EPS growth.

Among 10 analysts covering Loxo Oncology Inc (NASDAQ:LOXO), 9 have Buy rating, 1 Sell and 0 Hold. Therefore 90% are positive. Loxo Oncology Inc had 30 analyst reports since July 29, 2015 according to SRatingsIntel. As per Wednesday, November 11, the company rating was maintained by Stifel Nicolaus. Stifel Nicolaus maintained Loxo Oncology, Inc. (NASDAQ:LOXO) rating on Tuesday, August 8. Stifel Nicolaus has “Buy” rating and $9400 target. The company was maintained on Tuesday, August 4 by Oppenheimer. The rating was upgraded by Citigroup to “Buy” on Monday, June 5. Cowen & Co maintained the shares of LOXO in report on Monday, June 5 with “Buy” rating. Citigroup initiated Loxo Oncology, Inc. (NASDAQ:LOXO) on Monday, January 18 with “Buy” rating. Zacks upgraded Loxo Oncology, Inc. (NASDAQ:LOXO) on Friday, August 28 to “Sell” rating. The firm earned “Buy” rating on Wednesday, February 8 by Jefferies. The stock of Loxo Oncology, Inc. (NASDAQ:LOXO) earned “Overweight” rating by Morgan Stanley on Friday, October 6. On Tuesday, August 29 the stock rating was downgraded by JMP Securities to “Market Perform”.

Since August 14, 2017, it had 0 buys, and 17 selling transactions for $68.83 million activity. On Monday, September 18 Burstein Jennifer sold $151,470 worth of Loxo Oncology, Inc. (NASDAQ:LOXO) or 1,700 shares. $1.10 million worth of stock was sold by Bilenker Joshua H. on Monday, August 14. 7,250 shares were sold by Flaherty Keith T., worth $523,883 on Monday, August 21. The insider Bonita David P sold $20.63M. Naider Avi Z. had sold 5,000 shares worth $450,000 on Monday, September 18. $226,753 worth of Loxo Oncology, Inc. (NASDAQ:LOXO) was sold by Van Naarden Jacob. AISLING CAPITAL III LP sold $20.13M worth of Loxo Oncology, Inc. (NASDAQ:LOXO) on Tuesday, December 19.

Investors sentiment decreased to 1.73 in Q3 2017. Its down 2.10, from 3.83 in 2017Q2. It fall, as 13 investors sold LOXO shares while 35 reduced holdings. 31 funds opened positions while 52 raised stakes. 29.06 million shares or 49.34% less from 57.37 million shares in 2017Q2 were reported. Schwab Charles Investment reported 0.01% of its portfolio in Loxo Oncology, Inc. (NASDAQ:LOXO). Weiss Multi holds 15,000 shares or 0.05% of its portfolio. Bvf Inc Il invested 2.79% of its portfolio in Loxo Oncology, Inc. (NASDAQ:LOXO). California State Teachers Retirement holds 36,594 shares or 0.01% of its portfolio. Connecticut-based Trexquant Investment Ltd Partnership has invested 0.09% in Loxo Oncology, Inc. (NASDAQ:LOXO). The California-based Eam Limited Liability Com has invested 0.58% in Loxo Oncology, Inc. (NASDAQ:LOXO). The Nebraska-based Ameritas Inv has invested 0.01% in Loxo Oncology, Inc. (NASDAQ:LOXO). State Street owns 959,132 shares. Baker Bros Ltd Partnership stated it has 0.07% of its portfolio in Loxo Oncology, Inc. (NASDAQ:LOXO). Citadel Limited Liability Corp has 35,477 shares. Parametric Port Assocs Ltd has invested 0% in Loxo Oncology, Inc. (NASDAQ:LOXO). Ny State Common Retirement Fund stated it has 0% of its portfolio in Loxo Oncology, Inc. (NASDAQ:LOXO). Balyasny Asset Mgmt Lc reported 27,280 shares or 0.01% of all its holdings. Maryland-based Price T Rowe Assocs Inc Md has invested 0.01% in Loxo Oncology, Inc. (NASDAQ:LOXO). Ubs Asset Americas stated it has 207,041 shares or 0.02% of all its holdings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>